Heather Preston is Partner and Managing Director of TPG Biotech.  Prior to joining TPG Biotech
in May 2005, Dr. Preston spent two years at JP Morgan Partners where she focused on medical device and biotechnology venture capital investing. Prior to JP Morgan Partners, Dr. Preston was an
Entrepreneur-in-Residence with New Enterprise Associates. She also spent five years at McKinsey & Co.
in New York, where she was a leader of their pharmaceutical and medical products consulting
practice. She advised large pharmaceutical companies and biotechnology companies on
critical strategic issues such as R&D portfolio prioritization, M&A opportunities, new
technology acquisitions, new product launches and product growth strategies. Dr. Preston
has an undergraduate degree in biochemistry from the University of London and a
medical degree from the University of Oxford. Dr Preston completed a post-doctoral
fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University
and trained in Internal Medicine at the Massachusetts General Hospital and subspecialized
in Gastroenterology and Hepatology at UCSF. During her academic medical
career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research
Scholarship, a Harlech Scholarship and a Science and Engineering Research Council
Post-doctoral Fellowship Award.

Dr. Preston currently serves on the board of directors of Albireo, Inc (Nasdaq: ALBO).; Alder
BioPharmaceuticals (Nasdaq: ALDR); Otonomy, Inc. (Nasdaq: OTIC); Unchained Labs, Avalyn
Pharmaceuticals, MG Therapeutics and Entasis Inc. She previously served on the boards of
Aptalis Pharma (acquired by Forest Labs in February 2014), Conventus, Vibrynt, VLST and
Elevation Pharmaceuticals (acquired by Sunovion in September 2012) and is responsible for
overseeing TPG Biotech’s investment in Par Pharmaceuticals.

Dr. Preston also serves on the Board of Trustees for the Fine Arts Museums of San
Francisco, Saint Luke’s School and the Harlech Scholarship Foundation.